Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D. Demetri, Paolo G. Casali, Peter Hohenberger et al.|The Lancet|2012Cited by 1.4k
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing ResultsMichael C. Heinrich, Laurence H. Baker, Cathryn Rankin et al.|JAMA Oncology|2017Cited by 126
Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trialMartin E. Blackstein, George D. Demetri, Cathryn Rankin et al.|Journal of Clinical Oncology|2005Cited by 17